Treatment options for surgically resectable gastric cancer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Opinion statement: Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalCurrent Treatment Options in Oncology
Volume11
Issue number1-2
DOIs
StatePublished - Jun 2010

Fingerprint

Stomach Neoplasms
Stomach
Drug Therapy
Gastrointestinal Neoplasms
Survival
Biological Factors
Chemoradiotherapy
Therapeutics
Standard of Care
Combination Drug Therapy
Disease-Free Survival
Biomedical Research
Neoplasms
Adenocarcinoma
Survival Rate
Lymph Nodes
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Treatment options for surgically resectable gastric cancer. / Rajdev, Lakshmi.

In: Current Treatment Options in Oncology, Vol. 11, No. 1-2, 06.2010, p. 14-23.

Research output: Contribution to journalArticle

@article{2945e63590f74e9591d4b16b97cce211,
title = "Treatment options for surgically resectable gastric cancer",
abstract = "Opinion statement: Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.",
author = "Lakshmi Rajdev",
year = "2010",
month = "6",
doi = "10.1007/s11864-010-0117-1",
language = "English (US)",
volume = "11",
pages = "14--23",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1-2",

}

TY - JOUR

T1 - Treatment options for surgically resectable gastric cancer

AU - Rajdev, Lakshmi

PY - 2010/6

Y1 - 2010/6

N2 - Opinion statement: Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.

AB - Opinion statement: Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=77956228703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956228703&partnerID=8YFLogxK

U2 - 10.1007/s11864-010-0117-1

DO - 10.1007/s11864-010-0117-1

M3 - Article

C2 - 20358316

AN - SCOPUS:77956228703

VL - 11

SP - 14

EP - 23

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1-2

ER -